Vol.
30
No.
22
May 28, 2004May 28, 2004
Free

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.

Larry Norton wins ASCO’s Karnofsky award.

Funding opportunities listed.

May issue of Business & Regulatory Report, 8 additional pages, included.

Login